{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 23 of 128', 'Screening period', 'The screening period has a minimum duration of 1 week and a maximum', \"duration of 4 weeks. At the screening visit, the subjects' eligibility to enter the\", 'trial will be checked. The subjects will receive training in completion of an', 'electronic diary (eDiary). Furthermore, the subjects will be asked to fill out', 'patient-reported outcomes (PROs).', 'Treatment period', \"At baseline (Day 1), subjects' eligibility to enter the trial will be confirmed and\", 'if still eligible and IGA baseline severity and regional capping have not been', 'reached, the subjects will be randomised to 1 of the 5 treatment groups. The', 'randomisation is stratified by the severity of chronic hand eczema according to', 'IGA (mild, moderate, and severe) and region (Europe and North America).', 'The first application of the investigational medicinal product (IMP) will occur', 'at the trial site at baseline (Day 1). The subsequent IMP applications will be', 'performed by the subjects at home twice daily for 16 weeks. During the', 'treatment period, the subjects will be required to return to the trial site for the', 'visits scheduled at Weeks 1, 2, 4, 6, 8, 10, 12, 14, and 16. The last IMP', 'application will occur before the subjects attend the visit scheduled at Week 16.', 'Follow-up period', 'All subjects will attend a follow-up visit approximately 2 weeks after the last', 'IMP application for assessment of safety.', 'Screening', 'Treatment', 'Follow-up', 'Delgocitinib cream 20 mo/o (b.i.d.)', 'Delgocitinib cream 8 mg/g (b./.d.)', '250 subjects', '1:1:1:1:1', 'randomisation', 'Delgocitinib cream 3 mg/g (b.i.d.)', 'stratified by region &', 'IGA baseline s\u00e9verity', 'Delgocitinib cream 1 mg/g (b.i.d.)', 'Delgocitinib cream vehicle (b.i.d.)', 'Primary jendpoint', 'Visit No.', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '-28d', '-Td 1d', '29d', '57d', '85d', '113d', '127d', '-4w', '-1w Ow', '4w', '8w', '12w', '16w', '1Bw', 'Time from start of treatment', 'Main assessments', 'Investigator assessments of efficacy:', 'IGA for assessment of disease severity.', 'HECSI for assessment of the clinical signs of chronic hand eczema.', 'Subject assessments of efficacy and health-related quality of life; PROs:']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 24 of 128', 'Chronic Hand Eczema Symptom Diary (HESD).', 'Chronic Hand Eczema Impact Scale (HEIS).', \"Patient's Global Assessment (PaGA) of disease severity.\", 'Patient Global Impression of Change (PGI-C)', 'Dermatology Life Quality Index (DLQI).', 'EuroQoL 5-dimension health questionnaire 5-level (EQ-5D-5L).', 'Quality of Life in Hand Eczema Questionnaire (QOLHEQ).', 'Work Limitation Questionnaire (WLQ).', 'Safety assessments:', 'Vital signs, physical examinations, electrocardiograms, laboratory', 'testing, subject assessment of local tolerability, and adverse event', 'reporting.', 'Main criteria for', 'Age 18 years or above.', 'inclusion', 'Diagnosis of chronic hand eczema defined as hand eczema, which has', 'persisted for more than 3 months or returned twice or more within the', 'last 12 months.', 'Disease severity graded as mild to severe according to IGA (i.e.,', 'IGA>2).', 'Recent history (within 1 year before the screening visit) of inadequate', 'response to topical corticosteroid treatment or topical corticosteroid', 'treatment being medically inadvisable.', 'Diagnostic patch testing performed within 3 years prior to the', 'screening visit.', 'Main criteria for', 'Concurrent skin diseases on the hands, e.g. tinea manuum.', 'exclusion', 'Active atopic dermatitis in regions other than the hands or psoriasis', 'requiring medical treatment.', 'Clinically significant infection (e.g., impetiginised hand eczema) on the', 'hands.', 'Systemic treatment with immunosuppressive drugs (e.g., methotrexate,', 'cyclosporine, azathioprine), immunomodulating drugs (e.g., janus', 'kinase inhibitors), retinoids (e.g., alitretinoin), or corticosteroids within', '4 weeks prior to baseline (inhaled or intranasal steroids corresponding', 'to up to 1 mg prednisolone for asthma or rhinitis may be used).', 'Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the', 'hands within 4 weeks prior to baseline.', 'Receipt of live attenuated vaccines 4 weeks prior to baseline.', 'Cutaneously applied treatment with immunomodulators (e.g.,', 'phosphodiesterase-4 (PDE-4) inhibitors, pimecrolimus, tacrolimus) or', 'topical corticosteroids on the hands within 2 weeks prior to baseline.', 'Use of systemic antibiotics or cutaneously applied antibiotics on the', 'hands within 2 weeks prior to baseline.']\n\n###\n\n", "completion": "END"}